AbbVie receives a positive reimbursement recommendation from the Canadian Agencies for Drugs and Technology in Health (CADTH) pan-Canadian Oncology Drug Review Expert Review Committee (pERC) for Venclexta (venetoclax) in combination with azacitidine for acute myeloid leukaemia patients

26 August 2021 - pERC recommends reimbursement of Venclexta (venetoclax) in combination with azacitidine for the treatment of newly diagnosed acute ...

Read more →

Roche Canada announces collaboration to improve access to personalised health care with real world evidence

28 May 2021 - BC Cancer, CPHIN and Roche Canada will co-create an evidence-generating framework to leverage real-world data and facilitate ...

Read more →

'I would be able to live into my thirties:' Nova Scotia woman has high hopes for new cancer treatment

21 May 2021 - Maria Stevens was diagnosed with cervical cancer two years ago. Now, with a new treatment on ...

Read more →

Coverage of oncology medicines well aligned across Canadian provinces, but sources of funding differ

4 May 2021 - The Patented Medicine Prices Review Board, through the National Prescription Drug Utilisation Information System research initiative, today ...

Read more →

GSK’s Zejula is recommended for reimbursement by CADTH and INESSS for advanced ovarian cancer following response to first-line platinum-based chemotherapy

4 May 2021 - Zejula (niraparib) has received conditional positive recommendations for reimbursement from the Canadian Agency of Drugs and Technology ...

Read more →

CCRM and Amgen partner to advance emerging medical innovations

29 April 2021 - New fund to support regenerative medicine discoveries with high potential impact for patients. ...

Read more →

Bavencio receives reimbursement recommendation from pCODR and INESSS for the maintenance treatment of patients with advanced bladder cancer

29 April 2021 - EMD Serono Canada and Pfizer Canada are pleased to announce that Bavencio (avelumab for injection) has received ...

Read more →

Kite's Yescarta (axicabtagene ciloleucel) reimbursed in Alberta for the treatment of certain types of aggressive non-Hodgkin lymphoma

23 April 2021 - Gilead Canada announced today that Yescarta (axicabtagene ciloleucel) is now available in Alberta as a treatment ...

Read more →

CADTH publishes initial recommendation for nivolumab for NSCLC

9 January 2021 - The pERC has conditionally recommended the reimbursement of nivolumab when used in combination with ipilimumab and ...

Read more →

CADTH publishes initial pCODR recommendation for entrectinib

9 January 2021 - pERC has conditionally recommended the reimbursement of entrectinib for the first-line treatment of patients with ROS1 positive ...

Read more →

CADTH publishes final recommendation for Blincyto

29 October 2020 - The pERC final recommendation is based on a reconsideration of the initial recommendation and feedback from eligible ...

Read more →

Sales of cancer fighting drugs soared in Canada over the past decade

29 October 2020 - Canada is the only country with a universal health care system without coverage for prescription drugs. ...

Read more →

Radiopharmaceutical cancer treatment Lutathera now available to Ontario patients with midgut neuroendocrine tumours

8 October 2020 - Lutathera is the first and only therapeutic radiopharmaceutical approved by Health Canada for the treatment of GEP-NETs. ...

Read more →

Radiopharmaceutical Lutathera now reimbursed in Quebec for cancer patients with advanced gastro-enteropancreatic neuroendocrine tumours

1 October 2020 - Lutathera is the first and only therapeutic radiopharmaceutical indicated in the treatment of GEP-NETs in Canada. ...

Read more →

Roche Canada announces FoundationOne Liquid CDx now available in Canada

8 September 2020 - Comprehensive pan-tumour liquid biopsy test analyzes >300 cancer-associated genes and multiple genomic signatures to inform treatment choices. ...

Read more →